Pathological involvement of the noradrenergic locus coeruleus occurs early in Parkinson’s disease, and widespread noradrenaline reductions are found at post-mortem. Rapid eye movement sleep behaviour disorder (RBD) accompanies Parkinson’s disease and its presence predicts an unfavourable disease course with a higher propensity to cognitive impairment and orthostatic hypotension. MRI can detect neuromelanin in the locus coeruleus while 11C-MeNER PET is a marker of noradrenaline transporter availability. Here, we use both imaging modalities to study the association of RBD, cognition and autonomic dysfunction in Parkinson’s disease with loss of noradrenergic function. Thirty non-demented Parkinson’s disease patients [16 patients with RBD and 14 without RBD, comparable across age (66.6 ± 6.7 years), sex (22 males), and disease stage (Hoehn and Yahr, 2.3 ± 0.5)], had imaging of the locus coeruleus with neuromelanin sensitive MRI and brain noradrenaline transporter availability with 11C-MeNER PET. RBD was confirmed with polysomnography; cognitive function was assessed with a neuropsychological test battery, and blood pressure changes on tilting were documented; results were compared to 12 matched control subjects. We found that Parkinson’s disease patients with RBD showed decreased locus coeruleus neuromelanin signal on MRI (P < 0.001) and widespread reduced binding of 11C-MeNER (P < 0.001), which correlated with amount of REM sleep without atonia. Parkinson’s disease with RBD was also associated with a higher incidence of cognitive impairment, slowed EEG activity, and orthostatic hypotension. Reduced 11C-MeNER binding correlated with EEG slowing, cognitive performance, and orthostatic hypotension. In conclusion, reduced noradrenergic function in Parkinson’s disease was linked to the presence of RBD and associated with cognitive deterioration and orthostatic hypotension. Noradrenergic impairment may contribute to the high prevalence of these non-motor symptoms in Parkinson’s disease, and may be of relevance when treating these conditions in Parkinson’s disease.
Wearable automated detection devices of focal epileptic seizures are needed to alert patients and caregivers and to optimize the medical treatment. Heart rate variability (HRV)-based seizure detection devices have presented good detection sensitivity. However, false alarm rates (FAR) are too high. In this phase-2 study we pursued to decrease the FAR, by using patient-adaptive logistic regression machine learning (LRML) to improve the performance of a previously published HRV-based seizure detection algorithm. ECG-data were prospectively collected using a dedicated wearable electrocardiogram-device during long-term video-EEG monitoring. Sixty-two patients had 174 seizures during 4,614 h recording. The dataset was divided into training-, cross-validation-, and test-sets (chronological) in order to avoid overfitting. Patients with >50 beats/min change in heart rate during first recorded seizure were selected as responders. We compared 18 LRML-settings to find the optimal algorithm. The patient-adaptive LRML-classifier in combination with using only responders to train the initial decision boundary was superior to both the generic approach and including non-responders to train the LRML-classifier. Using the optimal setting of the LRML in responders in the test dataset yielded a sensitivity of 78.2% and FAR of 0.62/24 h. The FAR was reduced by 31% compared to the previous method, upholding similar sensitivity. The novel, patient-adaptive LRML seizure detection algorithm outperformed both the generic approach and the previously published patient-tailored method. The proposed method can be implemented in a wearable online HRV-based seizure detection system alerting patients and caregivers of seizures and improve seizure-count which may help optimizing the patient treatment.